PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Exclusion Criteria

• •Recent history of other malignancies
• •History of active autoimmune disorders
• •Any form of primary immunodeficiency
• •Active and clinically significant bacterial, fungal, or viral infection
• •Evidence of active mucosal or internal bleeding
• •History of severe immune-mediated adverse event with prior immunomodulatory treatment
• •Major surgery within 4 weeks of study treatment start
• •Radiation therapy within 2 weeks of study treatment start
• •History of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment
• •Donor Lymphocyte Infusion (DLI) within 30 days prior to study entry
• •Less than 30 days since last dose of antibody based therapies or less than 5 half-lives since last dose of previous therapy
• •Requirement for systemic immune suppressive medication except as permitted in the protocol
• •Current requirement for chronic blood product support